ERBB2 and breast cancer: Preclinical experiments are now available to demonstrate that FUS and microbubbles in combination with weekly trastuzumab therapy enhance BBB permeability, improving efficacy in mice inoculated with HER2-positive mammary tumors in the brain, notably decreasing the average intracerebral tumor volume, as well as a substantially enhancing the survival duration of the mice [119].